Seeking Alpha

Celgene (CELG +0.7%) says that abstracts reviewing results from a phase III metastatic melanoma...

Celgene (CELG +0.7%) says that abstracts reviewing results from a phase III metastatic melanoma study with Abraxane for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal. Results from the study show that the drug demonstrates significant improvement in progression-free survival when compared to standard chemotherapy in advanced melanoma patients. (abstract)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|